ClinicalTrials.govpublic full text
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
psoriasis, skin diseases, skin diseases, papulosquamous, adalimumab, anti-inflammatory agents, abbv-066, bi 655066, risankizumab, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 892972
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.